CA2270286C - Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device - Google Patents

Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device Download PDF

Info

Publication number
CA2270286C
CA2270286C CA002270286A CA2270286A CA2270286C CA 2270286 C CA2270286 C CA 2270286C CA 002270286 A CA002270286 A CA 002270286A CA 2270286 A CA2270286 A CA 2270286A CA 2270286 C CA2270286 C CA 2270286C
Authority
CA
Canada
Prior art keywords
vegf
use according
blood vessel
protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002270286A
Other languages
English (en)
French (fr)
Other versions
CA2270286A1 (en
Inventor
John Francis Martin
Seppo Yla-Herttuala
Stephen George Edward Barker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ark Therapeutics Ltd
Original Assignee
Eurogene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9622852.3A external-priority patent/GB9622852D0/en
Priority claimed from GBGB9709494.0A external-priority patent/GB9709494D0/en
Priority claimed from GBGB9717791.9A external-priority patent/GB9717791D0/en
Application filed by Eurogene Ltd filed Critical Eurogene Ltd
Publication of CA2270286A1 publication Critical patent/CA2270286A1/en
Application granted granted Critical
Publication of CA2270286C publication Critical patent/CA2270286C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Prostheses (AREA)
  • External Artificial Organs (AREA)
CA002270286A 1996-11-01 1997-11-03 Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device Expired - Fee Related CA2270286C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9622852.3 1996-11-01
GBGB9622852.3A GB9622852D0 (en) 1996-11-01 1996-11-01 Treatment of intimal hyperplasma
GBGB9709494.0A GB9709494D0 (en) 1997-05-09 1997-05-09 Delivery device and method
GB9709494.0 1997-05-09
GBGB9717791.9A GB9717791D0 (en) 1997-08-21 1997-08-21 Treatment of intimal hyperplasia
GB9717791.9 1997-08-21
PCT/GB1997/003015 WO1998020027A2 (en) 1996-11-01 1997-11-03 Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device

Publications (2)

Publication Number Publication Date
CA2270286A1 CA2270286A1 (en) 1998-05-14
CA2270286C true CA2270286C (en) 2009-03-03

Family

ID=27268562

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002270286A Expired - Fee Related CA2270286C (en) 1996-11-01 1997-11-03 Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device

Country Status (14)

Country Link
US (1) US7320679B2 (enExample)
EP (2) EP1488761A1 (enExample)
JP (3) JP2001503755A (enExample)
KR (1) KR100695590B1 (enExample)
AT (1) ATE287271T1 (enExample)
AU (1) AU729420B2 (enExample)
CA (1) CA2270286C (enExample)
DE (1) DE69732304T2 (enExample)
ES (1) ES2235227T3 (enExample)
HU (1) HU223957B1 (enExample)
NO (1) NO326303B1 (enExample)
PL (1) PL189744B1 (enExample)
PT (1) PT941116E (enExample)
WO (1) WO1998020027A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US20080305999A1 (en) * 1996-11-01 2008-12-11 John Francis Martin Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
EP1019082B2 (en) 1997-10-02 2008-06-04 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections
GB9809082D0 (en) 1998-04-28 1998-06-24 Eurogene Limited Delivery device
ATE253934T1 (de) * 1998-09-09 2003-11-15 Scios Inc Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien
US6596699B2 (en) 1998-09-22 2003-07-22 Biosurface Engineering Technologies, Inc. Nucleic acid coating compositions and methods
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
FR2792531B1 (fr) * 1999-04-26 2003-01-31 Aventis Pharma Sa Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
HUP0200961A3 (en) * 1999-04-26 2004-11-29 Inst Nat Sante Rech Med Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
ATE364387T1 (de) * 1999-09-23 2007-07-15 An Go Gen Inc Zellbasierte gentherapie für das lungensystem
JP2003513105A (ja) * 1999-11-02 2003-04-08 ジェネンテック・インコーポレーテッド ｅＮＯＳ活性の調節とその治療的使用
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
SE0000285D0 (sv) * 1999-12-07 2000-01-31 Mika Lahtinen Medical implant
AU3988401A (en) 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
GB0012997D0 (en) * 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
WO2002096469A2 (en) * 2001-05-29 2002-12-05 Ark Therapeutics Ltd. Gene delivery via a baculovirus vector
EP1406559A1 (en) * 2001-07-06 2004-04-14 Tricardia, L.L.C. Anti-arrhythmia devices and methods of use
SE0102578L (sv) * 2001-07-20 2003-01-21 Oeyvind Reitan Förändring av en stents egenskaper för att förhindra restenos
CA2526643A1 (en) * 2003-06-18 2004-12-29 Georg-August-Universitat Gottingen Use of a vegf receptor gene or gene product
GB0515140D0 (en) * 2005-07-22 2005-08-31 Ark Therapeutics Ltd Therapeutic device
ES2363758T3 (es) 2005-08-15 2011-08-16 Vegenics Pty Ltd Vegf y pdgf modificados con propiedades angiogénicas mejoradas.
JP2009523807A (ja) * 2006-01-18 2009-06-25 ザ ジェネラル ホスピタル コーポレイション リンパ機能を高める方法
US8721711B2 (en) 2007-06-20 2014-05-13 Oregon Health & Science University Graft having microporous membrane for uniform fluid infusion
CA2746807A1 (en) * 2007-12-14 2009-06-25 Oregon Health & Science University Drug delivery cuff
DE102008002396A1 (de) * 2008-06-12 2009-12-17 Biotronik Vi Patent Ag Implantierbares Wirkstoffreservoir und Vorrichtung mit einem implantierbaren Wirkstoffreservoir
JP6562632B2 (ja) * 2012-02-14 2019-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現
WO2013135266A1 (en) 2012-03-12 2013-09-19 Gemvax As Treatment of non-small cell lung carcinoma by active immunotherapy
CN104684561A (zh) 2012-08-01 2015-06-03 联合治疗公司 利用间充质干细胞的肺动脉高血压的治疗
KR102466885B1 (ko) 2013-01-09 2022-11-11 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린 및 중간엽 줄기 세포를 사용한 혈관병증의 치료
JP7179723B2 (ja) 2016-10-24 2022-11-29 ユナイテッド セラピューティクス コーポレイション トレプロスチニルによるｍｓｃの免疫調節特性の増強
CN114040923B (zh) * 2019-04-05 2024-11-26 韩国窑业技术院 利用肌集钙蛋白标签的蛋白质的表达及纯化方法
IT201900012537A1 (it) * 2019-07-22 2021-01-22 Milano Politecnico Dispositivo di condizionamento per condizionare un tratto esposto di un vaso sanguigno e metodo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797485A (en) * 1971-03-26 1974-03-19 Alza Corp Novel drug delivery device for administering drug into blood circulation in blood vessel
JPS56122317A (en) * 1980-02-29 1981-09-25 Koken:Kk Drug transporting material and its preparation
US5326568A (en) * 1991-05-03 1994-07-05 Giampapa Vincent C Method of tissue-specific delivery
US5201728A (en) * 1991-05-03 1993-04-13 Giampapa Vincent C Subcutaneous implantable multiple-agent delivery system
US5399352A (en) * 1993-04-14 1995-03-21 Emory University Device for local drug delivery and methods for using the same
EP0702518B1 (en) * 1993-06-11 2003-04-02 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5653744A (en) * 1995-04-27 1997-08-05 Khouri Biomedical Research, Inc. Device and method for vascular anastomosis
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor

Also Published As

Publication number Publication date
CA2270286A1 (en) 1998-05-14
PL189744B1 (pl) 2005-09-30
US20030225020A1 (en) 2003-12-04
EP0941116B1 (en) 2005-01-19
NO326303B1 (no) 2008-11-03
JP2008155036A (ja) 2008-07-10
HUP9902867A3 (en) 2001-12-28
PL333272A1 (en) 1999-11-22
HUP9902867A2 (hu) 1999-12-28
WO1998020027A2 (en) 1998-05-14
AU4790697A (en) 1998-05-29
DE69732304D1 (de) 2005-02-24
ATE287271T1 (de) 2005-02-15
WO1998020027A3 (en) 1998-10-08
JP4783797B2 (ja) 2011-09-28
JP2012031196A (ja) 2012-02-16
US7320679B2 (en) 2008-01-22
PT941116E (pt) 2005-05-31
NO992106D0 (no) 1999-04-30
KR20000052999A (ko) 2000-08-25
AU729420B2 (en) 2001-02-01
EP1488761A1 (en) 2004-12-22
EP0941116A2 (en) 1999-09-15
DE69732304T2 (de) 2005-06-02
NO992106L (no) 1999-06-30
ES2235227T3 (es) 2005-07-01
HU223957B1 (hu) 2005-03-29
KR100695590B1 (ko) 2007-03-14
JP2001503755A (ja) 2001-03-21
HK1108845A1 (zh) 2008-05-23

Similar Documents

Publication Publication Date Title
AU729420B2 (en) Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
US5851521A (en) Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
US8455453B2 (en) Use of VEGF-D gene to prevent restenosis
JP5231587B2 (ja) Ｖｅｇｆ−ｃまたはｖｅｇｆ−ｄ遺伝子またはタンパク質を用いた再狭窄の予防
US20070287682A1 (en) Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US20120308522A1 (en) Therapeutic Use of Growth Factor, and Delivery Device, Especially for the Treatment of Intimal Hyperplasia
EP0591408A1 (en) Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
AU745017B2 (en) Method of inhibiting smooth muscle cell proliferation
EP1073427B1 (en) Periadventitial delivery device
MXPA99004088A (en) Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
US20020034505A1 (en) Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
HK1108845B (en) Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device
EP1568375A1 (en) Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
US20090214496A1 (en) Bmx/etk tyrosine kinase gene therapy materials and methods
Cable et al. Gene therapy for vein graft disease
US20060093653A1 (en) Periadventitial delivery device
CN1981887A (zh) 生长因子的治疗用途和特别用于内膜增生治疗的输送装置
MXPA00010167A (es) Dispositivo para suministro periadventicio

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131105